Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–39 of 15 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Netarsudil Clear all

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Netarsudil Ophthalmic Solution 0.02%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 22
States / cities: Huntington Beach, California • Laguna Hills, California • Petaluma, California + 18 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: PG324 Ophthalmic Solution 0.01%, PG324 Ophthalmic Solution 0.02%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 23
States / cities: Artesia, California • Inglewood, California • Newport Beach, California + 20 more

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution, Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 30
States / cities: Dothan, Alabama • Phoenix, Arizona • Garden Grove, California + 25 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Fuchs' Endothelial Dystrophy, Bullous Keratopathy
Interventions: Netarsudil, Placebo; Drug
Lead sponsor: Cornea Research Foundation of America; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions: Netarsudil Ophthalmic; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fuchs' Endothelial Dystrophy
Interventions: Netarsudil Ophthalmic; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 40 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Corneal Edema
Interventions: Netarsudil Ophthalmic; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 12
States / cities: Garden Grove, California • Laguna Hills, California • Edgewood, Kentucky + 9 more

Conditions: Healthy Subjects
Interventions: Netarsudil (AR-13324) Ophthalmic Solution, Netarsudil (AR-13324) Ophthalmic Solution Placebo; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Glaucoma
Interventions: Rocklatan 0.02%-0.005% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Eye Centers of Southeast Texas; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Beaumont, Texas

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, Latanoprost ophthalmic solution 0.005%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 22
States / cities: Artesia, California • Inglewood, California • Newport Beach, California + 19 more

Conditions: Fuchs Endothelial Dystrophy
Interventions: Netarsudil Ophthalmic Solution, Placebo; Drug
Lead sponsor: Price Vision Group; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Open Angle Glaucoma
Interventions: Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Prairie Eye Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Springfield, Illinois

Search by objective public record fields.

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation

Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment

Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty

Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy

A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers

Rocklatan vs Latanoprost Post-DSLT

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost